InvestorsHub Logo
Followers 87
Posts 6634
Boards Moderated 1
Alias Born 09/18/2009

Re: dloggold post# 42099

Wednesday, 03/20/2024 3:39:56 PM

Wednesday, March 20, 2024 3:39:56 PM

Post# of 42709
You and I both posted here initially in 2015, so your opinion of me is based on a pretty complete awareness of my conclusions. I may have been able to make a more complete case, for instance, in regards to the share recall, perhaps if those records weren't sealed, and if we saw the charges against Dale's entities. The SEC didn't waste any time after the Kalobios squeeze, and charges against Dale's entities go all the way back to the very time that we became Humanigen. Still, I think Dale very likely won his Appeal. The share structure was managed meticulously, and I believe we will see a float of ~229M shares, which will cause a monster short squeeze when the loaned shares are recalled.

You are correct in saying that an opportunity with Novavax exists only in my head. There's been no sign of it otherwise. But they are the prime candidate that would qualify to use our lenz/vaccine patent, and I think they will have that opportunity as the deadly mRNA vaccines are losing market share, even before the Humanigen/Novavax product comes to market.

Hopefully, we have a pretty decent revenue stream from Gracell, and also hopefully we will be able to snag Tera-Immune, especially if Sanofi expands our opportunity to use the Treg process. Sanofi has always had a complimentary product line to Humanigen, and I look forward to the spin-off of their healthcare business. Don't discount that potential. They were here even before we showed up in 2015.